This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Pre-Conference Workshops

Pre-Conference Workshops are offered as part of the "All Access Conference & Workshop Pass" and will take place in-person on Monday, September 20, 2021 at the BCEC in Boston, MA.


Workshop #1: Path to a Successful IND/IMPD for Oligonucleotide Therapeutics
Jennifer Lockridge, Ph.D., Senior Vice President, Program Development, Dicerna Pharmaceuticals, Inc.
G. Susan Srivatsa, Ph.D. , President, ElixinPharma


Workshop #2: Best Practices in Peptide Drug Development: Avoiding Pitfalls and Roadblocks through the Product Lifecycle

Workshop Leaders:

  • Gary F. Musso, Ph.D., President, Musso and Associates LLC
  • Bruce Morimoto, Ph.D., Vice President, Cerecin

Best Practices for Nonclinical Peptide Development:  Bioanalysis, Pharmacokinetics, and Toxicity
Bruce Morimoto, Ph.D., Vice President, Cerecin

Formulation Development
Christopher Rhodes, Ph.D., President and CEO, Drug Delivery Experts 

CMC Regulatory Strategies for Peptides
Gary F. Musso, Ph.D., President, Musso and Associates LLC


Workshop #3: To be announced


Workshop #4: Strategies and Alternative Technologies for the Manufacturing Process of Therapeutic Oligonucleotides

Workshop Leaders:

  • Marc J. Jacob, Ph.D., Director of Business Development, Analytical Services, Ampac Analytical Laboratories Services
  • Marc Lemaitre, Ph.D., Consultant, ML Consult

Practical Applications of P-V Methodology Towards the Synthesis of Stereo-pure Oligonucleotides
Ravi Natarajan, Ph.D., President, Socrates Biosciences

The Use of Boronic Acid for the Chromatography of Oligonucleotides
Christopher Gabriel, Ph.D., Senior Scientist, Process Organic Chemistry, Ionis Pharmaceuticals, Inc.

Purification of Synthetic Oligonucleotides: A CMO Perspective
Ralf Eisenhuth, Ph.D., Scientific Expert API Production, Bachem AG

P(III) vs. P(V): A P(V) Reagent for Thiophosphoramidate Linkages and Application to An Asymmetric Synthesis of a Cyclic Dinucleotide STING Agonist
Michael Schmidt, Scientist, Bristol-Myers Squibb 


Workshop #5: FDA Draft Guidance on ANDA Filings for Peptides

Workshop Leader:

  • Trishul Shah, Director, Business Development, North America, PolyPeptide Laboratories

Methods for Assessing the Immunogenicity of Peptide Drugs and Their Impurities
Annie De Groot, M.D., Professor (Research) and Annie De Groot, M.D., Professor (Research) and Director, Institute for Immunology and Informatics, University of Rhode Island and Founder, CEO and CSO, EpiVax, Inc., USA  

Considerations in Submitting Abbreviated New Drug Application of Generic Peptide Drug Products
Deyi Zhang, Ph.D., Senior Chemist, Office of Research and Standards, Office of Generic Drugs, CDER, US FDA


Workshop #6: To be announced

Keynote Sessions

These keynote sessions will be offered as part of all TIDES USA conference passes. They will take place in-person on September 21 at the live event, and will be available on-demand for all digital attendees from September 28-30, 2021. More keynote speakers/sessions will be added.

My Long Road from the 2’-5’ Oligos to the mRNA Vaccine
Katalin Karikó, Ph.D., Senior Vice President RNA Protein Replacement Therapy, BioNTech RNA Pharmaceuticals GmbH, Germany

RNAi Therapeutics: Past, Present, and (Mostly) Future
John Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals

Antisense Oligonucleotides for the Treatment of Neurological Diseases
Holly Kordasiewicz, Ph.D., Vice President Neurology Research, Ionis Pharmaceuticals

Approved Commercial Peptide Vyleesi and A Family of Melanocortin Peptides in Late Stage Development
Carl Spana, CEO, Palatin Technologies

Discovery and Development of Rusfertide (PTG-300) Being Developed for Treatment of PV 
David Liu, Ph.D. Chief Scientific Officer, Head of Discovery & Pre-Clinical Development, Protagonist Therapeutics

Main Conference Sessions

These sessions will be offered as part of all TIDES USA conference passes. They will take place in-person during the September 21-23 live event, and will be available on-demand for all digital attendees from September 28-30, 2021. More sessions will be added. 
TRACK: Oligonucleotide Discovery, Preclinical and Clinical

Oligonucleotide Discovery Program Update
Tasuku Kitada, Ph.D., President and Head of R&D, Strand Therapeutics 

Investigations into Disruptive Delivery Approaches for LNA ASOs - Evaluation of Bovine Milk Derived Extracellular Vesicles as Oral DDS
Michael Keller, Ph.D., Senior Principal Scientist, pCMC Drug Delivery and Preformulation Sciences, Roche pRED, Switzerland

DCR-AUD program
Bob D. Brown, Ph.D., Chief Scientific Officer and Senior Vice President, Research, Dicerna Pharmaceuticals

Identification and Optimization of a Minor Allele-specific siRNA to Prevent PNPLA3 I148M-driven Nonalcoholic Fatty Liver Disease
Justin Murray, Ph.D., Senior Principal Scientist, Selection & Modality Engineering, Amgen

CNS Oligonucleotides
Moderator: Yogesh Sanghvi, Ph.D., President, Rasayan, Inc. 

Treating Repeat Expansion Disorders by Stopping Somatic Expansion
Brian Bettencourt, Ph.D., SVP Research, Triplet Therapeutics

Nucleic Acid Chemical Modifications  
Moderator: Punit P. Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals

Old Dogs and New Puppies of Chemical Modifications for RNA Therapeutics
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

Chemical Modification of Guide RNA to Improve the CRISPR- Cas9 Activity for Genome Editing
Rubina Parmar, Ph.D., Senior Director, Chemistry and Delivery Sciences, Intellia Therapeutics 

Oligonucleotide Backbone Engineering for Enhancing Metabolic Stability, Potency, and Selectivity of siRNAs 
Ken Yamada, Ph.D., Assistant Professor, University of Massachusetts Medical School

Exploring New Oligonucleotide Backbone Chemistries and Their Deployment to Improve the Properties of Stereopure Oligonucleotides
Chandra Vargeese, Ph.D., SVP, Head of Drug Discovery, WAVE Life Sciences  

Redefining the Chemical Space for Antisense Therapeutics
Punit P. Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals

Sequence-specific Recognition of Double-stranded RNA by Cationic Nucleobase and Backbone-modified Peptide Nucleic Acids
Eriks Rozners, Ph.D., Professor and Chair of Chemistry Department, Binghamton University

Emerging Oligonucleotide Drug Discovery 
Moderator: Troels Koch, Ph.D., Industry Expert

Targeting ANGPTL4 in the Liver with ASO – A Novel Treatment for Cardiometabolic Disease
Stefan Nilsson, Ph.D., CEO, Lipigon Pharmaceuticals AB, Sweden

U1 Adaptors Bioconjugates for Targeted Gene Silencing in Extrahepatic Tissues
P. Peter Ghoroghchian, M.D., Ph.D., President and CEO, Silagene, Inc.

A Novel, RNA-based Anti-viral Approach to Limit BK Virus Propagation in Immunocompromised Patients
Eric van der Veer, Ph.D., Chief Scientific Officer, Hybridize Therapeutics, The Netherlands

Platform Optimization to Enable Therapeutic Development of ADAR-mediated RNA editing 
Stuart Milstein, Ph.D., VP Platform Biology, Korro Bio

Targeted Delivery of Therapeutic Oligonucleotides 
Moderator: Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

Improved Delivery of RNA Therapeutics in the Eye, Muscle, and Beyond Using Fatty-Acid Conjugation 
Charles R. Allerson, Ph.D., Vice President of Chemistry & Drug Development, DTx Pharma

Targeted Delivery of Base Editors to Hepatocytes in vivo
Kallanthottathil Rajeev, Ph.D., Vice President, CMC, Verve Therapeutics 

Delivery of RNA Therapeutics: The Great Endosomal Escape!
Steven Dowdy, Ph.D., Professor, Cellular and Molecular Medicine, UCSD School of Medicine 

Antibody Oligonucleotide Conjugates: Taking Receptor-Mediated Uptake One Step Further
Arthur Levin, Ph.D., Chief Scientific Officer, Avidity Biosciences

Muscle Targeted Delivery of Therapeutic Oligonucleotides with the FORCE™ Platform
Oxana Beskrovnaya, Ph.D., Senior Vice President, Head of Research, Dyne Therapeutics

Targeted Delivery of Therapeutics
Karyn O'Neil, Ph.D., Co-founder and CSO, Aro Biotherapeuitics

Targeted Delivery of ASO Therapeutics
Punit P. Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals

Development of An antimiR-based Therapy to Treat Myotonic Dystrophy Disease
Beatriz Llamusí Troísi, Arthex Biotech

TRACK: Oligonucleotide Chemistry, Manufacturing and Controls

Improved Oxidizer Formulations for the Synthesis of PO/PS Mixed Backbone Oligonucleotides
Andrew Rodriguez, Ph.D., Associate Director, Process Chemistry, Ionis Pharmaceuticals

Analytics of Oligonucleotides 
Moderator: Claus Rentel, Ph.D., Executive Director, Analytical Development/QC, Ionis Pharmaceuticals

Automated Online UPLC and Data Processing for Oligonucleotide Synthesis and Purification Monitoring
Andrew Argo, Scientist I, Quality Control Analytical Technology-Advanced Process Control, Biogen

Analytical Method Development of Complementary Related Organic Impurity Methods for Oligonucleotides
Chris Gripton, Ph.D., Investigator, Drug Substance and Product Analysis UK, CMC Analytical, GSK Medicines Research Centre, United Kingdom

Manufacturing and Analytical Challenges of Oligonucleotide Lipid Delivery Systems and Their Translation to the Clinic
Angela Wagner, Associate Principal Scientist, Sterile & Specialty, Merck

Developing Methods to Control Critical Impurities in Phosphoramidites
Dennis Rhodes, Assistant Director, Analytical Development and QC, Ionis Pharmaceuticals

Identification and Quantitation of Thermal Degradation Products of Antisense oligonucleotides (ASOs) Enables Understanding of Degradation Mechanism
Rasika Phansalkar, Ph.D., Scientist I, Technical Development, Biogen

Sustainable Manufacturing of Oligonucleotides
Moderator: Firoz D. Antia, Ph.D., Director, Antisense Oligonucleotide Process Development and Manufacturing, Biogen

Sustainability Challenges and Opportunities in Oligonucleotide Manufacturing
Ben Andrews, Ph.D., Investigator, Chemical Development, GlaxoSmithKline, United Kingdom 

Oligonucleotide Starting Materials – Drivers (or Disasters) for Sustainability
Louis Diorazio, Ph.D., Principal Scientist, Chemical Development, AstraZeneca, United Kingdom

Development of a Scalable Synthesis Process for Oligonucleotides
Xianglin Shi, Ph.D., Head  of Oligonucleotide Chemical Process Development, Biogen

Issues to Resolve for Very Large-Scale Oligonucleotide Manufacturing 
Anthony Scozzari, Vice President, Development Chemistry & Manufacturing, Ionis Pharmaceuticals

TRACK: Peptide Discovery, Preclinical and Clinical

Solid-Phase Peptide Synthesis Using a Four-Dimensional Protecting Group Scheme
Fernando Albericio, Ph.D., Research Professor, School of Chemistry, University of Kwazulu-Natal, South Africaram

Discovery and Optimization of Long-acting, Unimolecular Peptide Triple Agonists of the GLP-1, GIP, and Glucagon Receptors
Patrick J. Knerr, Ph.D., Research Scientist II – Chemistry, Novo Nordisk Research Center Indianapolis

Journey Beyond the Margin: Development of Imaging System to Assist Tumor Resections
Jorge Ferrer, Ph.D., SVP of Clinical Research and Strategy, Lumicell

Peptide Clinical Candidates for Rare Diseases 
Moderator: Jesper Lau, Ph.D., Vice President, Chemical Biology, Novo Nordisk A/S, Denmark

Oral Delivery of PTH 1-34 in the Treatment of Hypoparathyroidism and Osteoporosis
Phillip Schwartz, Ph.D., President of R&D and EVP, Entera Bio Ltd., Israel  

Targeted Radioligand Therapies, Diagnostic Imaging and Peptide Receptor Radionuclide Therapy 
Moderator: Jesse Z. Dong, Ph.D., Vice President, Peptide Chemistry, BioNTech, USA

Tumor-targeted Radionuclides Using De Novo Macrocyclic Peptide-mimetics
Deborah Charych, Ph.D., Chief Technology Officer and Co-founder, RayzeBio, Inc.

Peptides Radiopharmaceuticals
Joe McCann, CEO, Point Biopharmaceuticals

Targeted Alpha Therapeutics to Improve the Safety of Radiopharmaceuticals
John Rhoden, Ph.D., Director, Preclinical Development, Fusion Pharmaceuticals

30 Years of Peptide Nucleic Acids and On the Road to Precision Antisense Antibiotics Against Multidrug Resistant Bacteria
Peter E. Nielsen, Ph.D., Professor, Center for Peptide-Based Antibiotics, University of Copenhagen, Denmark

Latest Advances in PNA Research
Dietrich Stephan, CEO, Neubase Therapeutics 

TRACK: Peptide Chemistry, Manufacturing and Controls

Refractive Index: The Ultimate Tool for Real-Time Monitoring of Solid-Phase Peptide Synthesis. Greening the Process
Beatriz de la Torre, Ph.D., Research Professor, Laboratory of Medicine and Medical Sciences, University of KwaZulu-Natal 

Peptides for COVID-19 Therapy 
Moderator: Trishul Shah, Director, Business Development, North America, PolyPeptide Laboratories

Case Study of Rapid Acceleration of Manufacturing for a COVID Vaccine
Tim Culbreth, Site Director, Polypeptide

Peptide Treatment for COVID-19 Symptoms
Jonathan Javitt, CEO, NeuroRx 

TRACK: mRNA Therapeutics/Vaccines & Genome Editing

mRNA Therapeutics, Vaccines and Applications
Moderator: Nicole Roth, Ph.D., Senior Scientist, CureVac AG, Germany

A Novel Vaccine Approach Using Messenger RNA‐Lipid Nanoparticles: Preclinical and Clinical Perspective
Ying Tam, Ph.D., Chief Scientific Officer, Acuitas Therapeutics, Inc.

Subcutaneous Administration of mRNA
Nigel Davies, Scientist, AstraZeneca

Development of Broadly Protective Influenza Vaccines Using Nucleoside-modified mRNA
Norbert Pardi, Ph.D., Research Assistant Professor of Medicine, University of Pennsylvania  

Genome Editing Advances to the Clinic
Moderators: Cecilia Fernández, Ph.D., Cecilia Fernández, Strategy and Operations, 5AM Ventures and
Rubina Parmar, Ph.D., Director, Chemistry, Intellia Therapeutics

Clinical Progress in Genome Editing 
Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics

Analytical Characterization of Guide RNAs and Ribonucleoproteins for CRISPR Applications
Steven Wolk, Ph.D., Senior Director of Analytical Chemistry, Editas Medicine

In vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates
Andrew Bellinger, M.D., Ph.D., CSO, Verve Therapeutics 

Non-Viral Delivery Platform Work with Preclinical Data
Delai Chen, Ph.D., Associate Director Nanoparticle Formulation, Beam Therapeutics